A study of expression levels of the interferon regulated genes in Japanese systemic lupus erythematosus patients with moderate to severe disease activities and healthy adults

Not Applicable

• Conditions: Systemic lupus erythematosus

• Registration Number: JPRN-UMIN000009040
• Lead Sponsor: Chugai Pharmaceutical co., ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-10-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

Not provided

Exclusion Criteria

(ERL/LN) -Unstable neuropsychiatric SLE at the time of sampling. -Evidence of significant uncontrolled concomitant diseases (e.g., cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders) at the time of sampling. -Conditions other than SLE that could require treatment with corticosteroids (e.g., asthma) at the time of within 12 months prior to sampling. -History of cancer within 5 years prior to sampling. -History of congenital immunodeficiency. -Signs or symptoms of infection within 31 days prior to sampling (Healthy adults) -Evidence of concomitant diseases (e.g., cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders) at the time of sampling. -History of cancer within 5 years prior to sampling. -Any clinically abnormal conditions at the time of sampling. -Signs or symptoms of infection within 31 days prior to sampling.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IRGs expression levels in Japanese SLE patients